Advertisement

Topics

Search Results for "Butal Acet Caff 50 325 40mg"

03:39 EDT 19th August 2017 | BioPortfolio

Matching Channels

None

Matching News

Global and Chinese Aceto Acet 4Chloro Ortho Toluidine Industry, 2017 Market Research Report [Report Updated: 01011970] Prices from USD $3000

The 'Global and Chinese Aceto Acet 4Chloro Ortho Toluidine Industry, 20122022 Market Research Report' is a professional and indepth study on the current state of the global Aceto Acet 4Chloro Ortho To...

FDA approves hypertension generic

Brian BerkJubilant Pharma’s olmesartan medoxomil Tablets 5mg/20mg, 5mg/40mg, 10mg/20mg and 10mg/40mg is the generic version of Daiichi Sankyo’s Azor. read more

Payer Insights: MS [2016]: Bulletin 3 [Updated: 01052017] Prices from USD $1045

Topics covered in this update include: payers' approaches to the reimbursement of Ocrevus ocrelizumab; Roche/Biogen for relapsing remitting multiple sclerosis RRMS and primary progressive multiple scl...

Multiple Sclerosis Payer Insight: Update Bulletin [April 2017] [Updated: 01042017] Prices from USD $1045

Topics covered in this update include: payers' approaches to the reimbursement of Ocrevus ocrelizumab; Roche/Biogen for relapsing remitting multiple sclerosis RRMS and primary progressive multiple scl...

Osimertinib receives full approval in the EU

The European Commission (EC) has granted full marketing authorisation for osimertinib 40mg and 80mg once-daily tablets for the treatment of adult patients with locally-advanced or metastatic epiderm...

Boehringer Ingelheim initiates interchangeability trial of BI 695501 and Humira

Boehringer Ingelheim has initiated patient enrolment in an interchangeability clinical trial (VOLTAIRE-X) of its product candidate BI 695501 and the US-marketed formulation of 40mg/0.8mL Humira.

AstraZeneca Granted Full Marketing Authorisation For Tagrisso In EU

LONDON (dpa-AFX) - AstraZeneca (AZN.L) announced the European Commission has granted full marketing authorisation for Tagrisso (osimertinib) 40mg and 80mg once-daily tablets for the treatment of a...

EC approves AstraZeneca’s Tagrisso to treat mutation-positive NSCLC

AstraZeneca has secured full marketing authorization from the European Commission (EC) for its Tagrisso (osimertinib) 40mg and 80mg once-daily tablets to treat adult patients with locally-advanced or ...

Matching PubMed Articles

AFB1 hepatocarcinogenesis is via lipid peroxidation that inhibits DNA repair, sensitizes mutation susceptibility and induces aldehyde-DNA adducts at p53 mutational hotspot codon 249.

Aflatoxin B1 (AFB1) contamination in the food chain is a major cause of hepatocellular carcinoma (HCC). More than 60% of AFB1 related HCC carry p53 codon 249 mutations but the causal mechanism remains...

Rapid mixing with high-throughput in a semi-active semi-passive micromixer.

In this paper, we investigate a novel alternating current electrothermal (ACET) micromixer driven by a high efficiency ACET micropump. The micromixer consists of thin film asymmetric pairs of electrod...

Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.

The ibogaine derivative 18-methoxycoronaridine (18-MC) has been found to decrease self-administration of morphine, nicotine and alcohol in rats after systemic injection. However oral dosing is the pre...

Methyl jasmonate attenuates memory dysfunction and decreases brain levels of biomarkers of neuroinflammation induced by lipopolysaccharide in mice.

Neuroinflammation plays a central role in the etiology and progression of Alzheimer's disease (AD), a neurodegenerative disorder, characterized by a gradual loss of memory functions. Thus, it has been...

Adjusted value of thromboprophylaxis in hospitalized obese patients: A comparative study of two regimens of enoxaparin: The ITOHENOX study.

Thromboprophylaxis is a mainstay of hospital care in patients at high risk of thrombosis. Fixed doses of low-molecular-weight heparin (LMWH) are recommended for thromboprophylaxis in patients admitted...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement